Anistreplase

:

Anistreplase is a thrombolytic drug. These drugs alter plasminogen to plasmin,which in turn lowers the fibrin (blood clots) to the breakdown products of fibrin.

indications:

To clear a blockage in the arteries associated with myocardial infarction.

Dosage:

30 u through a blood vessel (intra venous) for 4-5 minutes as a single dose.

If the patient is at high risk of systemic thromboembolism or blood vessels, give:

Unfractionated heparin (UFH) through a vein (IV):

Give ≥ 4 hours after treatment when the PTT <70 seconds.

Target PTT should be around 50-70 seconds and the infusion should be continued for ≥ 48 hours.

Side Effects:

Haematological effects (especially bleeding from puncture wounds, severeinternal bleeding, bleeding intrakarnial); allergic reaction (rash, skin redness,urticaria, and anaphylatic a rather rare and serum disease like symptoms); Other effects (fever, chills with pain in the back and abdomen); Securities GI (N / V),Guillain-Barre syndrome

Infusion may be associated with hypotension (either directly or as a result ofreperfusion), bradycardia, and arrhythmias may occur due to reperfusion.

Destroy clots sometimes cause embolism anywhere.

More serious allergic reaction may occur with use of urokinase thanStreptokinase.

Special Instructions:

Anistreplase appear to be antigenic and can be neutralized by antibodiesStreptokinase.

Anti-streptokinase antibodies formed after about 5 days after the use ofStreptokinase.

These antibodies may cause resistance or hypersensitivity to the next doseStreptokinase.

It is recommended not to give Streptokianse 5 days - 12 months after the first(alternative thrombolytic can be used, except Anistreplase).